SCHEMBL13158360

SCHEMBL13158360

Cc1c(C(=O)NC2CC2)nnn1-c1ccc(NC(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 1/20 0.55
▸ PTGS2 P35354 3/20 0.52
▸ SMURF1 Q9HCE7 2/20 0.52
▸ LMNA P02545 2/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ POLB P06746 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ORAI1 Q96D31 1/20 0.44
▸ CNR1 P21554 1/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CCR1 P32246 1/20 0.43
▸ HSD11B1 P28845 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13158358 0.90 TP53 (0.55) TP53PTGS2LMNAHSP90AA1MAPT
SCHEMBL13158347 0.89 TP53 (0.64) TP53PTGS2LMNAHSP90AA1MAPT
SCHEMBL13158359 0.88 KMT2A (0.56) TP53SMURF1LMNAPOLBMAPT
SCHEMBL13158458 0.87 PTGS2 (0.52) TP53PTGS2SMURF1MAPTNPC1
SCHEMBL5243957 0.85 ROCK1 (0.46) LMNAMAPTKDM4EMEN1NPC1
SCHEMBL13158422 0.84 TP53 (0.52) TP53PTGS2SMURF1LMNAHSP90AA1
SCHEMBL13158460 0.83 RAB9A (0.53) TP53PTGS2SMURF1MAPTNPC1
SCHEMBL13158427 0.83 PTGS2 (0.49) TP53PTGS2SMURF1MAPTNPC1
SCHEMBL13158410 0.83 TP53 (0.51) TP53PTGS2SMURF1LMNAHSP90AA1
SCHEMBL13158351 0.83 TP53 (0.51) TP53PTGS2SMURF1LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 — — US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 TP53 2716/4885PTGS2 1750/4885SMURF1 4730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback